Organic Active Ingredients TRIZ Cases

Replacing expensive boron reagents with a catalytic palladium system to reduce production costs while maintaining high substrate selectivity.

Integrating NMDA pathway modulators with beta-alanine reduces sensory paraesthesia, allowing faster achievement of peak physical performance benefits.

Specific tetrapeptide motifs stimulate collagen synthesis to improve skin resilience while reducing irritation from traditional retinoids.

Borate complexes prevent nicotinamide ribose decomposition, resolving stability issues in cost-effective enzymatic synthesis.

Gas-filled cavities in solidified foam matrices enable rapid saliva penetration, resolving adherence and slow disintegration bottlenecks in high-mass wafers.

Amino-substituted imidazopyridazine compounds inhibit MKNK1 kinase to block eIF4E phosphorylation and suppress cancer cell proliferation.

GM-CSF antagonists reduce pro-inflammatory cytokines to improve lung function and lower mortality rates in acute respiratory distress syndrome.

Novel pyrido[4,3-e]pyrrolo[1,2-a]pyrazine compounds inhibit protein kinase CK2 activity with high potency against multiple cancer cell lines.

Heteroaryl inhibitors block aldosterone synthesis upstream, resolving breakthrough effects and halting diabetic nephropathy progression.

Embedding swellable agents in pH-sensitive coatings overcomes slow dissolution lag times, enabling rapid site-specific drug release in the intestine.

Selective RORγt inhibition reduces inflammation while preserving host defenses against infection and cancer.

Disulfide-crosslinked polymer coatings on antioxidant crystals release active ingredients upon oxidative exposure.

Sulfonamide and carboxamide derivatives selectively target ROR receptors, minimizing off-target effects on LXR nuclear receptors.

Gelatin-stabilized lipid particles shield insulin from gastric degradation, enabling oral bioavailability and reducing injection frequency.

N-carboxylmethyl-D-leucyl-L-prolyl amide hydrochloride acts as a competitive thrombin inhibitor.

Unbranched linker amino acid compounds inhibit alpha V beta 6 integrin to address the lack of effective long-term treatments for pulmonary and liver fibrosis.

Segmenting thyroid receptors into distinct isoforms allows selective beta agonists to lower cholesterol without cardiac side effects.

Modifying the DNA template sequence upstream of the transcription start site resolves the contradiction between capping efficiency and byproduct formation.

Amide derivatives modulate hepatitis B virus capsid assembly to reduce viral load while avoiding drug resistance from polymerase inhibitors.

Formula I compounds modulate gamma-secretase activity, reducing Aβ42 production while avoiding NSAID side effects.

Iron oxide nanoparticles enable MRI tracking of dendritic cell migration within RNA-loaded liposomes, resolving the complexity of nuclear medicine imaging.

Hydroxylation of kinase inhibitors using cytochrome P450 monooxygenase resolves the contradiction between Abl kinase efficacy and cardiovascular side effects.

Modified cyclic dinucleosides activate the STING pathway to induce type I interferon, addressing limited modulation of inflammatory conditions.

Nitroimidazole compounds accumulate in hypoxic regions to overcome radioresistance and improve treatment reliability.

Statistical copolymers with controlled anionic groups absorb lysozyme while limiting polycationic component uptake.

FEN1 inhibitors prevent mtDNA fragmentation and subsequent NLRP3 inflammasome activation, addressing chronic inflammation in metabolic diseases.

Calebin A mediates cartilage protection by penetrating the dense matrix and inhibiting chondrocyte apoptosis despite restricted cellular migration.

Co-administering bupropion with dextromethorphan inhibits CYP2D6 metabolism, resolving low plasma levels in extensive metabolizers.

Human IMPACs secrete paracrine factors to modulate immune responses and promote wound healing in cardiac tissues.

A method precipitates ferric trihydroxypyrone from an aqueous alkaline solution using controlled pH adjustment to ensure pharmaceutical purity.

Pyrido-azacyclic compounds overcome c-Met resistance mutations by optimizing substituent groups to enhance binding affinity and selectivity.

Multiple-network pseudo-interpenetrating polymer network hydrogels enable strain-induced drug release through mechanical deformation.

Formula I compounds inhibit KIT, CSF1R, and PDGFR kinases to address abnormal activation in autoimmune diseases.

dCas9-based epigenomic editors remove H3K9me3 marks to reactivate silenced genes.

Amphipathic alpha-helical stapled peptide achieves high cell penetration at nanomolar concentrations by combining hydrophobic and hydrophilic amino acids.

Transferring a solubilized excipient mixture containing hydrofluoroalkane propellant and polyethylene oxide polymer into a vessel with active compound.

E-selectin antagonists mobilize hematopoietic stem cells from bone marrow, addressing high failure rates of existing agents in lymphoma and leukemia patients.

A humanized monoclonal antibody binds the CCR5 receptor to block CCL5 ligand interaction without triggering agonist activity.

A ribonucleoprotein base editor complex performs precise gene correction by reducing off-target effects.

Diazotization of aminonaphthalene and cresol creates a multifunctional compound that neutralizes free radicals to overcome bacterial resistance.

Anti-PRLR antibody-drug conjugates target tumor cells expressing the prolactin receptor to deliver cytotoxic payloads directly to cancer sites.

Laundry treatment systems recharge cosmetocompression garments, resolving the contradiction between sustained health benefits and convenient recharging.

Surfactant and polyol co-solvents dissolve lipophilic Compound I in aqueous vehicle, avoiding salt formation costs while maintaining stability.